Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Gabriela S Hobbs"'
Autor:
Lipika Goyal, Mark Cobbold, Rakesh K Jain, Ivy X Chen, Ayako Shigeta, Daniel Staiculescu, Dieter Zopf, Lukas Fiebig, Gabriela S Hobbs, Peigen Huang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background and purpose Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific mechanisms of benefit remain u
Externí odkaz:
https://doaj.org/article/3a16c10d09a0429d990a0dd5f6981ee3
Autor:
Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 434-442 (2022)
Abstract We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory
Externí odkaz:
https://doaj.org/article/b768134a01424428b03dc52b7afb2c56
Autor:
Aaron T. Gerds, Prithviraj Bose, Gabriela S. Hobbs, Andrew T. Kuykendall, Lynn M. Neilson, Jinlin Song, Barbara Klencke, Claire N. Harrison
Publikováno v:
HemaSphere, Vol 6, Iss 10, p e778 (2022)
Externí odkaz:
https://doaj.org/article/2e5b93e70ad742e4913c8e5b0100cf6d
Autor:
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 106-111 (2020)
Abstract: Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1 fusion oncogene. I
Externí odkaz:
https://doaj.org/article/7fc7238856444e36b2853dd5b133bf4f
Autor:
Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver
Publikováno v:
Blood. 140:579-582
Autor:
Andrew M. Brunner, Traci M. Blonquist, Gabriela S. Hobbs, Philip C. Amrein, Donna S. Neuberg, David P. Steensma, Gregory A. Abel, Amir T. Fathi
Publikováno v:
Blood Advances, Vol 1, Iss 23, Pp 2032-2040 (2017)
Abstract: Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders associated with progression to leukemia and poor survival. Clonal hematopoiesis in people without an MDS diagnosis carries an increased risk of cardiovascular deat
Externí odkaz:
https://doaj.org/article/79a1f4f592d84054b970852a59157929
Autor:
Matthew L Chase, Reed E. Drews, Alfred I Lee, Erin G Reid, Aaron T. Gerds, Gabriela S. Hobbs, Leslie R Ellis, Marc S Zumberg, Jonathan Berry, Jason A Freed
Publikováno v:
Blood. 140:10781-10783
Autor:
Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss
Publikováno v:
Blood. 140:3284-3286
Autor:
Areej El-Jawahri, Selina M. Luger, Nina O'Connor, Annemarie D. Jagielo, Amir T. Fathi, Thomas W. LeBlanc, Bhavana Bhatnagar, Matthew J. Reynolds, Jason A. Webb, Andrew M. Brunner, Carlisle E.W. Topping, Alison R. Kavanaugh, Dagny M. Vaughn, Gabriela S. Hobbs, P. Connor Johnson
Publikováno v:
Journal of Palliative Medicine. 25:749-756
Background: Patients (≥60 years) with acute myeloid leukemia (AML) often receive intense health care utilization at the end of life (EOL). However, factors associated with their health care use at the EOL are unknown. Methods: We conducted a second
Autor:
Debra Van Egeren, Baransel Kamaz, Shichen Liu, Maximilian Nguyen, Christopher R. Reilly, Maria Kalyva, Daniel J. DeAngelo, Ilene Galinsky, Martha Wadleigh, Eric S. Winer, Marlise R. Luskin, Richard M. Stone, Jacqueline S. Garcia, Gabriela S. Hobbs, Franziska Michor, Isidro Cortes-Ciriano, Ann Mullally, Sahand Hormoz
Publikováno v:
Exp Hematol
The JAK2-V617F mutation is the most common cause of myeloproliferative neoplasms. While experiments have shown that this gain-of-function mutation is associated with myeloid blood cell expansion and increased production of white cells, red cells and